Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15834107 | 1.00 | HPGD (0.41) | HPGDSMN1; SMN2TSHRALDH1A1LMNA | |
| SCHEMBL13744668 | 1.00 | HPGD (0.41) | HPGDSMN1; SMN2TSHRALDH1A1LMNA | |
| SCHEMBL12888245 | 0.84 | SMN1; SMN2 (0.50) | HPGDSMN1; SMN2ALDH1A1LMNAKMT2A | |
| SCHEMBL8538369 | 0.84 | TSHR (0.39) | HPGDSMN1; SMN2TSHRALDH1A1LMNA | |
| SCHEMBL21185861 | 0.84 | ALDH1A1 (0.39) | HPGDSMN1; SMN2ALDH1A1LMNAKMT2A | |
| SCHEMBL87923 | 0.81 | TSHR (0.41) | HPGDSMN1; SMN2TSHRALDH1A1LMNA | |
| SCHEMBL87924 | 0.81 | HPGD (0.40) | HPGDSMN1; SMN2TSHRALDH1A1LMNA | |
| SCHEMBL12732931 | 0.79 | LMNA (0.45) | HPGDSMN1; SMN2TSHRALDH1A1LMNA | |
| SCHEMBL18769009 | 0.79 | SMN1; SMN2 (0.39) | HPGDSMN1; SMN2TSHRALDH1A1LMNA | |
| SCHEMBL5194330 | 0.79 | FAAH (0.49) | HPGDSMN1; SMN2ALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014100730-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20090209511-A1 | Benzofuran Derivatives | KAWAGUCHI TAKAYUKI | 2009-08-20 | — | — | US | disclosed |
| US-20090209511-A1 | Benzofuran Derivatives | KAWAGUCHI TAKAYUKI | 2009-08-20 | — | — | US | disclosed |
| US-7531537-B2 | Benzofuran derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209511-A1 | Benzofuran Derivatives | F12, F2, F3 | HPGD 850/4885SMN1; SMN2 3067/4885TSHR 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.